Market Place
Sourcing Support
Genentech`s Giredestrant Cuts Er-Positive Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
Roche Links SERD to 30% Breast Cancer Risk Reduction in Phase 3
10 Dec 2025 //
GLOBENEWSWIRE
Genentech`s Giredestrant Shows Superior iDFS in Breast Cancer
18 Nov 2025 //
BUSINESSWIRE
EMPRESS Study Shows Giredestrant Cut Tumor Growth in Early Cancer
20 Oct 2025 //
PR NEWSWIRE
ESMO: Roche Wants Oral SERD To Benefit `All Comers`
18 Oct 2025 //
FIERCE BIOTECH
Roche Showcases Science And Cancer Care Advances At ESMO 2025
13 Oct 2025 //
GLOBENEWSWIRE
Roche Reports Phase 3 Breast Cancer Victory for Oral Serd
24 Sep 2025 //
FIERCE BIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.